Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols TLE5 and PRDM1	Name 1 TLE family member 5, transcriptional modulator	Name2 PR/SET domain 1	Pathway 1 Repression of WNT target genes	Pathway 2 Regulation of TP53 Expression STAT3 nuclear events downstream of ALK signaling Specification of primordial germ cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FASN and SNX8	Name 1 fatty acid synthase	Name2 sorting nexin 8	Pathway 1 ChREBP activates metabolic gene expression Vitamin B5 (pantothenate) metabolism Activation of gene expression by SREBF (SREBP) Fatty acyl-CoA biosynthesis Fatty acyl-CoA biosynthesis NR1H2 & NR1H3 regulate gene expression linked to lipogenesis	Pathway 2	Drugs 1 Cerulenin Orlistat	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ATXN1 and ZNF276	Name 1 ataxin 1	Name2 zinc finger protein 276	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel Novel	Symbols ATXN1 and LITAF	Name 1 ataxin 1	Name2 lipopolysaccharide induced TNF factor	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel Novel	Symbols ATXN1 and CUTC	Name 1 ataxin 1	Name2 cutC copper transporter	Pathway 1	Pathway 2 Ion transport by P-type ATPases	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel Novel	Symbols MAPK14 and MOB3B	Name 1 mitogen-activated protein kinase 14	Name2 MOB kinase activator 3B	Pathway 1 NOD1/2 Signaling Pathway p38MAPK events p38MAPK events ERK/MAPK targets Activation of PPARGC1A (PGC-1alpha) by phosphorylation Oxidative Stress Induced Senescence ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL VEGFA-VEGFR2 Pathway activated TAK1 mediates p38 MAPK activation Activation of the AP-1 family of transcription factors KSRP (KHSRP) binds and destabilizes mRNA Myogenesis Myogenesis RHO GTPases Activate NADPH Oxidases Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A CD163 mediating an anti-inflammatory response Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2	Drugs 1 Minocycline Dasatinib 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One Inhibitor of P38 Kinase 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea 3-(Benzyloxy)Pyridin-2-Amine l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline Doramapimod 2-Chlorophenol 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole SB220025 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE Triazolopyridine KC706 Talmapimod VX-702 R-1487 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide Neflamapimod N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide PH-797804 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine SD-0006 N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BBS4 and HSCB	Name 1 Bardet-Biedl syndrome 4	Name2 HscB mitochondrial iron-sulfur cluster cochaperone	Pathway 1 BBSome-mediated cargo-targeting to cilium	Pathway 2 Mitochondrial protein import Mitochondrial protein import Mitochondrial iron-sulfur cluster biogenesis Complex I biogenesis Complex III assembly	Drugs 1	Drugs 2	Diseases 1 Bardet-Biedl syndrome (BBS)	Diseases 2
Novel Novel	Symbols PSMB5 and ABCB5	Name 1 proteasome 20S subunit beta 5	Name2 ATP binding cassette subfamily B member 5	Pathway 1 Activation of NF-kappaB in B cells Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha ER-Phagosome pathway Cross-presentation of soluble exogenous antigens (endosomes) Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Vpu mediated degradation of CD4 Vif-mediated degradation of APOBEC3G SCF(Skp2)-mediated degradation of p27/p21 Degradation of beta-catenin by the destruction complex Downstream TCR signaling Regulation of activated PAK-2p34 by proteasome mediated degradation Separation of Sister Chromatids FCERI mediated NF-kB activation Autodegradation of the E3 ubiquitin ligase COP1 Regulation of ornithine decarboxylase (ODC) ABC-family proteins mediated transport AUF1 (hnRNP D0) binds and destabilizes mRNA Asymmetric localization of PCP proteins Degradation of AXIN Degradation of DVL Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'on' state Regulation of RAS by GAPs TNFR2 non-canonical NF-kB pathway NIK-->noncanonical NF-kB signaling Defective CFTR causes cystic fibrosis MAPK6/MAPK4 signaling UCH proteinases Ub-specific processing proteases Assembly of the pre-replicative complex Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Ubiquitin-dependent degradation of Cyclin D The role of GTSE1 in G2/M progression after G2 checkpoint FBXL7 down-regulates AURKA during mitotic entry and in early mitosis RUNX1 regulates transcription of genes involved in differentiation of HSCs Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Regulation of RUNX3 expression and activity Regulation of PTEN stability and activity Neddylation Regulation of expression of SLITs and ROBOs Interleukin-1 signaling Negative regulation of NOTCH4 signaling KEAP1-NFE2L2 pathway GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 Degradation of CDH1 Somitogenesis Antigen processing: Ubiquitination & Proteasome degradation Proteasome assembly Proteasome assembly Antigen processing: Ub, ATP-independent proteasomal degradation GSK3B-mediated proteasomal degradation of PD-L1(CD274) SPOP-mediated proteasomal degradation of PD-L1(CD274) AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Degradation of CRY and PER proteins Degradation of CRY and PER proteins Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	Pathway 2 ABC-family proteins mediated transport	Drugs 1 Bortezomib (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE Carfilzomib	Drugs 2 Biricodar Dofequidar	Diseases 1	Diseases 2
Novel Novel	Symbols CSTF2 and CNOT2	Name 1 cleavage stimulation factor subunit 2	Name2 CCR4-NOT transcription complex subunit 2	Pathway 1 tRNA processing in the nucleus mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs	Pathway 2 Deadenylation of mRNA TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain M-decay: degradation of maternal mRNAs by maternally stored factors	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PEX12 and THSD7B	Name 1 peroxisomal biogenesis factor 12	Name2 thrombospondin type 1 domain containing 7B	Pathway 1 E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Peroxisomal protein import Class I peroxisomal membrane protein import	Pathway 2 Defective B3GALTL causes PpS O-glycosylation of TSR domain-containing proteins	Drugs 1	Drugs 2	Diseases 1 Zellweger syndrome spectrum, including: Zellweger syndrome (ZS); Adrenoleukodystrophy, neonatal (NALD); Infantile Refsum disease (IRD)	Diseases 2
Novel Novel	Symbols NCBP1 and NCBP2	Name 1 nuclear cap binding protein subunit 1	Name2 nuclear cap binding protein subunit 2	Pathway 1 SLBP independent Processing of Histone Pre-mRNAs Formation of RNA Pol II elongation complex Formation of the Early Elongation Complex Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of HIV-1 elongation complex containing HIV-1 Tat Abortive elongation of HIV-1 transcript in the absence of Tat snRNP Assembly RNA Polymerase II Pre-transcription Events FGFR2 alternative splicing RNA polymerase II transcribes snRNA genes mRNA Capping mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs Processing of Intronless Pre-mRNAs Signaling by FGFR2 IIIa TM Regulation of expression of SLITs and ROBOs Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Nuclear RNA decay	Pathway 2 SLBP independent Processing of Histone Pre-mRNAs Formation of RNA Pol II elongation complex Formation of the Early Elongation Complex Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of HIV-1 elongation complex containing HIV-1 Tat Abortive elongation of HIV-1 transcript in the absence of Tat snRNP Assembly RNA Polymerase II Pre-transcription Events FGFR2 alternative splicing RNA polymerase II transcribes snRNA genes mRNA Capping mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs Processing of Intronless Pre-mRNAs Signaling by FGFR2 IIIa TM Regulation of expression of SLITs and ROBOs Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Nuclear RNA decay	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NFE2L2 and PMF1	Name 1 NFE2 like bZIP transcription factor 2	Name2 polyamine modulated factor 1	Pathway 1 Neddylation Potential therapeutics for SARS Regulation of HMOX1 expression and activity Heme signaling KEAP1-NFE2L2 pathway KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 NFE2L2 regulating TCA cycle genes NFE2L2 regulating inflammation associated genes NFE2L2 regulating anti-oxidant/detoxification enzymes NFE2L2 regulates pentose phosphate pathway genes NFE2L2 regulating tumorigenic genes NFE2L2 regulating MDR associated enzymes NFE2L2 regulating ER-stress associated genes Regulation of NFE2L2 gene expression Regulation of NFE2L2 gene expression Regulation of PD-L1(CD274) transcription	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DLG4 and PCDH10	Name 1 discs large MAGUK scaffold protein 4	Name2 protocadherin 10	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DLG4 and SLC4A7	Name 1 discs large MAGUK scaffold protein 4	Name2 solute carrier family 4 member 7	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Bicarbonate transporters RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOJ GTPase cycle RHOF GTPase cycle	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols KPNA4 and ADNP	Name 1 karyopherin subunit alpha 4	Name2 activity dependent neuroprotector homeobox	Pathway 1 ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AP2M1 and CTLA4	Name 1 adaptor related protein complex 2 subunit mu 1	Name2 cytotoxic T-lymphocyte associated protein 4	Pathway 1 Nef mediated downregulation of CD28 cell surface expression Nef Mediated CD4 Down-regulation Retrograde neurotrophin signalling Retrograde neurotrophin signalling Nef Mediated CD8 Down-regulation Gap junction degradation Formation of annular gap junctions MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Recycling pathway of L1 Recycling pathway of L1 WNT5A-dependent internalization of FZD4 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDLR internalisation and degradation LDL clearance Potential therapeutics for SARS	Pathway 2 Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Drugs 1	Drugs 2 Abatacept Ipilimumab Tremelimumab	Diseases 1	Diseases 2 Graves' disease Allograft rejection Type I diabetes mellitus Hashimoto's thyroiditis
Novel Novel	Symbols BMPR2 and NBEA	Name 1 bone morphogenetic protein receptor type 2	Name2 neurobeachin	Pathway 1 Signaling by BMP	Pathway 2 Neurotransmitter receptors and postsynaptic signal transmission PKA activation NOTCH1 Intracellular Domain Regulates Transcription Assembly and cell surface presentation of NMDA receptors	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BMPR2 and FOXL1	Name 1 bone morphogenetic protein receptor type 2	Name2 forkhead box L1	Pathway 1 Signaling by BMP	Pathway 2	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BMPR2 and LSP1	Name 1 bone morphogenetic protein receptor type 2	Name2 lymphocyte specific protein 1	Pathway 1 Signaling by BMP	Pathway 2	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FXR1 and CA10	Name 1 FMR1 autosomal homolog 1	Name2 carbonic anhydrase 10	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2 Zonisamide	Diseases 1	Diseases 2
Novel	Symbols TLE5 and PRDM1	Name 1 TLE family member 5, transcriptional modulator	Name2 PR/SET domain 1	Pathway 1 Repression of WNT target genes	Pathway 2 Regulation of TP53 Expression STAT3 nuclear events downstream of ALK signaling Specification of primordial germ cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FASN and SNX8	Name 1 fatty acid synthase	Name2 sorting nexin 8	Pathway 1 ChREBP activates metabolic gene expression Vitamin B5 (pantothenate) metabolism Activation of gene expression by SREBF (SREBP) Fatty acyl-CoA biosynthesis Fatty acyl-CoA biosynthesis NR1H2 & NR1H3 regulate gene expression linked to lipogenesis	Pathway 2	Drugs 1 Cerulenin Orlistat	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ATXN1 and ZNF276	Name 1 ataxin 1	Name2 zinc finger protein 276	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel	Symbols ATXN1 and LITAF	Name 1 ataxin 1	Name2 lipopolysaccharide induced TNF factor	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel	Symbols ATXN1 and CUTC	Name 1 ataxin 1	Name2 cutC copper transporter	Pathway 1	Pathway 2 Ion transport by P-type ATPases	Drugs 1	Drugs 2	Diseases 1 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)	Diseases 2
Novel	Symbols MAPK14 and MOB3B	Name 1 mitogen-activated protein kinase 14	Name2 MOB kinase activator 3B	Pathway 1 NOD1/2 Signaling Pathway p38MAPK events p38MAPK events ERK/MAPK targets Activation of PPARGC1A (PGC-1alpha) by phosphorylation Oxidative Stress Induced Senescence ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL VEGFA-VEGFR2 Pathway activated TAK1 mediates p38 MAPK activation Activation of the AP-1 family of transcription factors KSRP (KHSRP) binds and destabilizes mRNA Myogenesis Myogenesis RHO GTPases Activate NADPH Oxidases Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A CD163 mediating an anti-inflammatory response Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2	Drugs 1 Minocycline Dasatinib 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One Inhibitor of P38 Kinase 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea 3-(Benzyloxy)Pyridin-2-Amine l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline Doramapimod 2-Chlorophenol 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole SB220025 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE Triazolopyridine KC706 Talmapimod VX-702 R-1487 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide Neflamapimod N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide PH-797804 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine SD-0006 N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BBS4 and HSCB	Name 1 Bardet-Biedl syndrome 4	Name2 HscB mitochondrial iron-sulfur cluster cochaperone	Pathway 1 BBSome-mediated cargo-targeting to cilium	Pathway 2 Mitochondrial protein import Mitochondrial protein import Mitochondrial iron-sulfur cluster biogenesis Complex I biogenesis Complex III assembly	Drugs 1	Drugs 2	Diseases 1 Bardet-Biedl syndrome (BBS)	Diseases 2
Novel	Symbols PSMB5 and ABCB5	Name 1 proteasome 20S subunit beta 5	Name2 ATP binding cassette subfamily B member 5	Pathway 1 Activation of NF-kappaB in B cells Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha ER-Phagosome pathway Cross-presentation of soluble exogenous antigens (endosomes) Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Vpu mediated degradation of CD4 Vif-mediated degradation of APOBEC3G SCF(Skp2)-mediated degradation of p27/p21 Degradation of beta-catenin by the destruction complex Downstream TCR signaling Regulation of activated PAK-2p34 by proteasome mediated degradation Separation of Sister Chromatids FCERI mediated NF-kB activation Autodegradation of the E3 ubiquitin ligase COP1 Regulation of ornithine decarboxylase (ODC) ABC-family proteins mediated transport AUF1 (hnRNP D0) binds and destabilizes mRNA Asymmetric localization of PCP proteins Degradation of AXIN Degradation of DVL Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'on' state Regulation of RAS by GAPs TNFR2 non-canonical NF-kB pathway NIK-->noncanonical NF-kB signaling Defective CFTR causes cystic fibrosis MAPK6/MAPK4 signaling UCH proteinases Ub-specific processing proteases Assembly of the pre-replicative complex Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Ubiquitin-dependent degradation of Cyclin D The role of GTSE1 in G2/M progression after G2 checkpoint FBXL7 down-regulates AURKA during mitotic entry and in early mitosis RUNX1 regulates transcription of genes involved in differentiation of HSCs Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Regulation of RUNX3 expression and activity Regulation of PTEN stability and activity Neddylation Regulation of expression of SLITs and ROBOs Interleukin-1 signaling Negative regulation of NOTCH4 signaling KEAP1-NFE2L2 pathway GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 Degradation of CDH1 Somitogenesis Antigen processing: Ubiquitination & Proteasome degradation Proteasome assembly Proteasome assembly Antigen processing: Ub, ATP-independent proteasomal degradation GSK3B-mediated proteasomal degradation of PD-L1(CD274) SPOP-mediated proteasomal degradation of PD-L1(CD274) AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Degradation of CRY and PER proteins Degradation of CRY and PER proteins Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	Pathway 2 ABC-family proteins mediated transport	Drugs 1 Bortezomib (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE Carfilzomib	Drugs 2 Biricodar Dofequidar	Diseases 1	Diseases 2
Novel	Symbols CSTF2 and CNOT2	Name 1 cleavage stimulation factor subunit 2	Name2 CCR4-NOT transcription complex subunit 2	Pathway 1 tRNA processing in the nucleus mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs	Pathway 2 Deadenylation of mRNA TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain M-decay: degradation of maternal mRNAs by maternally stored factors	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PEX12 and THSD7B	Name 1 peroxisomal biogenesis factor 12	Name2 thrombospondin type 1 domain containing 7B	Pathway 1 E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Peroxisomal protein import Class I peroxisomal membrane protein import	Pathway 2 Defective B3GALTL causes PpS O-glycosylation of TSR domain-containing proteins	Drugs 1	Drugs 2	Diseases 1 Zellweger syndrome spectrum, including: Zellweger syndrome (ZS); Adrenoleukodystrophy, neonatal (NALD); Infantile Refsum disease (IRD)	Diseases 2
Novel	Symbols NCBP1 and NCBP2	Name 1 nuclear cap binding protein subunit 1	Name2 nuclear cap binding protein subunit 2	Pathway 1 SLBP independent Processing of Histone Pre-mRNAs Formation of RNA Pol II elongation complex Formation of the Early Elongation Complex Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of HIV-1 elongation complex containing HIV-1 Tat Abortive elongation of HIV-1 transcript in the absence of Tat snRNP Assembly RNA Polymerase II Pre-transcription Events FGFR2 alternative splicing RNA polymerase II transcribes snRNA genes mRNA Capping mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs Processing of Intronless Pre-mRNAs Signaling by FGFR2 IIIa TM Regulation of expression of SLITs and ROBOs Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Nuclear RNA decay	Pathway 2 SLBP independent Processing of Histone Pre-mRNAs Formation of RNA Pol II elongation complex Formation of the Early Elongation Complex Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of HIV-1 elongation complex containing HIV-1 Tat Abortive elongation of HIV-1 transcript in the absence of Tat snRNP Assembly RNA Polymerase II Pre-transcription Events FGFR2 alternative splicing RNA polymerase II transcribes snRNA genes mRNA Capping mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs Processing of Intronless Pre-mRNAs Signaling by FGFR2 IIIa TM Regulation of expression of SLITs and ROBOs Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Nuclear RNA decay	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NFE2L2 and PMF1	Name 1 NFE2 like bZIP transcription factor 2	Name2 polyamine modulated factor 1	Pathway 1 Neddylation Potential therapeutics for SARS Regulation of HMOX1 expression and activity Heme signaling KEAP1-NFE2L2 pathway KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 NFE2L2 regulating TCA cycle genes NFE2L2 regulating inflammation associated genes NFE2L2 regulating anti-oxidant/detoxification enzymes NFE2L2 regulates pentose phosphate pathway genes NFE2L2 regulating tumorigenic genes NFE2L2 regulating MDR associated enzymes NFE2L2 regulating ER-stress associated genes Regulation of NFE2L2 gene expression Regulation of NFE2L2 gene expression Regulation of PD-L1(CD274) transcription	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG4 and PCDH10	Name 1 discs large MAGUK scaffold protein 4	Name2 protocadherin 10	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG4 and SLC4A7	Name 1 discs large MAGUK scaffold protein 4	Name2 solute carrier family 4 member 7	Pathway 1 Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Bicarbonate transporters RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOJ GTPase cycle RHOF GTPase cycle	Drugs 1 Guanidine Guanosine-5'-Monophosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols KPNA4 and ADNP	Name 1 karyopherin subunit alpha 4	Name2 activity dependent neuroprotector homeobox	Pathway 1 ISG15 antiviral mechanism NS1 Mediated Effects on Host Pathways	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AP2M1 and CTLA4	Name 1 adaptor related protein complex 2 subunit mu 1	Name2 cytotoxic T-lymphocyte associated protein 4	Pathway 1 Nef mediated downregulation of CD28 cell surface expression Nef Mediated CD4 Down-regulation Retrograde neurotrophin signalling Retrograde neurotrophin signalling Nef Mediated CD8 Down-regulation Gap junction degradation Formation of annular gap junctions MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Recycling pathway of L1 Recycling pathway of L1 WNT5A-dependent internalization of FZD4 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDLR internalisation and degradation LDL clearance Potential therapeutics for SARS	Pathway 2 Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Drugs 1	Drugs 2 Abatacept Ipilimumab Tremelimumab	Diseases 1	Diseases 2 Graves' disease Allograft rejection Type I diabetes mellitus Hashimoto's thyroiditis
Novel	Symbols BMPR2 and NBEA	Name 1 bone morphogenetic protein receptor type 2	Name2 neurobeachin	Pathway 1 Signaling by BMP	Pathway 2 Neurotransmitter receptors and postsynaptic signal transmission PKA activation NOTCH1 Intracellular Domain Regulates Transcription Assembly and cell surface presentation of NMDA receptors	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BMPR2 and FOXL1	Name 1 bone morphogenetic protein receptor type 2	Name2 forkhead box L1	Pathway 1 Signaling by BMP	Pathway 2	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BMPR2 and LSP1	Name 1 bone morphogenetic protein receptor type 2	Name2 lymphocyte specific protein 1	Pathway 1 Signaling by BMP	Pathway 2	Drugs 1 Dibotermin alfa Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FXR1 and CA10	Name 1 FMR1 autosomal homolog 1	Name2 carbonic anhydrase 10	Pathway 1 Signaling by BRAF and RAF1 fusions	Pathway 2	Drugs 1	Drugs 2 Zonisamide	Diseases 1	Diseases 2

Page 50 out of 98 pages

Search Results : Cancer